Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study

Fig. 1

Comparison of sunitinib and N-desethyl-sunitinib levels in plasma, serum and isolated platelets from mRCC patients on 2 and 4 weeks on treatment. The concentration of sunitinib (A) and N-desethyl-sunitinib (B) were measured in plasma and serum samples obtained from mRCC patients at 2 and 4 weeks of sunitinib treatment. (C) The concentrations of both compounds were determined in isolated platelets, normalized to ng per 2.5 × 108 platelets. Individual dots in the scatterplots represent one patient, for color coding see Table 1. Lines and error bars represent median ± interquartile range (n = 14-20). *P < 0.05. **P < 0.01, ***P < 0.001

Back to article page